Document is current
Any future updates will be listed below
-
Authors
Madhavan, Aparajita
Kok, Bernard P.
Rius, Bibiana
Grandjean, Julia M. D.
Alabi, Adekunle
Albert, Verena
Sukiasyan, Ara
Powers, Evan T.
Galmozzi, Andrea https://orcid.org/0000-0002-9411-7327
Saez, Enrique https://orcid.org/0000-0001-5718-5542
Wiseman, R. Luke https://orcid.org/0000-0001-9287-6840
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (DK114785, AG046495, DK123038)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 30 August 2021
Accepted: 18 January 2022
First Online: 1 February 2022
Competing interests
: R.L.W. is an inventor on a patent describing IRE1/XBP1s-activating compounds, including IXA4, and is a scientific advisory board member and shareholder in Protego Biopharma, which has licensed these compounds for translational studies. The authors declare no other competing interests.
